Retrospective but interesting: aspirin and BCR

[Maxone73]

A new retrospective study, published on Nature, has found that aspirin may help reduce biochemical recurrence (BCR) in prostate cancer patients following robot-assisted radical prostatectomy (RARP).

Analyzing data from over 8,000 patients across 25 centers, researchers observed that aspirin use, after statistical adjustments, was associated with improved 3-year BCR-free survival rates, particularly in high-risk cases with an ISUP grade of 4 or higher. While aspirin’s anti-cancer effects remain a topic of debate, this study suggests it could have a protective role by inhibiting cancer cell proliferation and angiogenesis.

The findings highlight the potential of aspirin as an accessible and cost-effective strategy to improve post-surgical outcomes in prostate cancer, though prospective trials are needed to confirm its effectiveness and determine optimal usage.

prostatewarriors.com/2025/0...

[Broccoli24]

Encouraging… I’ve been on 75mg daily for the last while. Every little helps.

[GreenStreet]

I am wondering when the add aspirin and separate add Vitamin D clinical trials in the U.K. will report. I went on the add aspirin trial over 6 years ago but discontinued it due to two reasons. Firstly although I had declared my use of supplements at the beginning of the trial at my first year review they reviewed them again and asked me to discontinue them. I preferred to keep taking my supplements. Also the trial had 2 different strengths of aspirin and a placebo and for all I knew I could have been on a placebo and yet still required to ditch my supplements. Since coming off the trial I take a baby aspirin every 3 days. The trial is designed to see whether aspirin reduces the time to metastases in patients where the primary treatment has not done the job. I wonder when it is due to report,

[Teufelshunde]

What dose was used? Was it dose dependent?